Edwards Lifesciences Forecast, price target & analysts
Edwards Lifesciences Target price 2026 - Analyst rating & recommendation
Edwards Lifesciences Classifications & Recommendation
Edwards Lifesciences Price Target
| Target Price | $103.02 |
| Price | $89.28 |
| Potential |
15.39%
register free of charge
|
| Number of Estimates | 32 |
|
32 Analysts have issued a price target Edwards Lifesciences 2027 .
The average Edwards Lifesciences target price is $103.02.
This is
15.39%
register free of charge
$115.50
29.37%
register free of charge
$85.85
3.84%
register free of charge
|
|
| A rating was issued by 40 analysts: 31 Analysts recommend Edwards Lifesciences to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Edwards Lifesciences stock has an average upside potential 2027 of
15.39%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 6.07 | 6.97 |
| 11.55% | 14.86% | |
| EBITDA Margin | 29.75% | 31.48% |
| 1.03% | 5.80% | |
| Net Margin | 17.69% | 25.55% |
| 76.95% | 44.41% |
36 Analysts have issued a sales forecast Edwards Lifesciences 2026 . The average Edwards Lifesciences sales estimate is
This results in the following potential growth metrics:
28 Analysts have issued an Edwards Lifesciences EBITDA forecast 2026. The average Edwards Lifesciences EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
35 Edwards Lifesciences Analysts have issued a net profit forecast 2026. The average Edwards Lifesciences net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.83 | 3.09 |
| 73.71% | 68.85% | |
| P/E | 28.91 | |
| EV/Sales | 6.86 |
35 Analysts have issued a Edwards Lifesciences forecast for earnings per share. The average Edwards Lifesciences EPS is
This results in the following potential growth metrics and future valuations:
Edwards Lifesciences...
Current Edwards Lifesciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Jul 24 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Jul 15 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Jul 24 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 16 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Jul 15 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jul 13 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
